InVivo Therapeutics reports a $4.8M net loss in 2018 Q1: 5 details

Spinal Tech

InVivo Therapeutics shared its first quarter 2018 financial results.

Here are five details.

1. In the first quarter, InVivo experiences a net loss of $4.8 million compared to a $6.4 million net loss in the same period in 2017.

2. Decreases in operating expenses allowed for a smaller net loss. The company reported $2 million in research and development expenses in the first quarter of 2018.

3. At the end of the quarter, InVivo had $11.6 million in cash and cash equivalents on hand.

4. During the first quarter, InVivo named Richard Toselli, MD, its president and CEO. He is a board-certified neurosurgeon.

5. InVivo also entered into a common stock purchase agreement with Lincoln Park Capital Fun to sell up to $15 million in shares of common stock to Lincoln Park.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers